Meningitis B at Princeton and the University of California at Santa Barbara: Postscript

ACADEME BLOG

In an earlier post, “Meningitis B at Princeton and at the University of California at Santa Barbara” (http://academeblog.org/2013/12/10/meningitis-b-at-princeton-at-the-university-of-california-at-santa-barbara/), I reported on the outbreaks of the disease among students at the two campuses and on the decision by the Centers for Disease Control to allow a vaccine not yet approved for use in the U.S. to be administered to at-risk students and staff at Princeton.

That vaccine, called Bexsero, is produced by the Swiss pharmaceutical company Novartis AG, and although vaccines for other strains of meningitis are available in the U.S., Bexero is the only vaccine for meningitis B available anywhere. It has already been approved for use in the European Union and in some nations outside Europe, but it has not yet even been submitted to the U.S. Federal; Drug Administration for approval. The company has provided the FDA and CDC with studies done in Europe that demonstrate…

View original post 817 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s